Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL7718872 | 0.78 | FOLH1 (0.48) | FNTAFNTBFOLH1METAP1NAALAD2 | |
| SCHEMBL11334546 | 0.74 | FOLH1 (0.43) | FOLH1NAALAD2 | |
| Butane SCHEMBL7009352 | 0.73 | FDPS (0.42) | FNTAFNTBMETAP1FDPS | |
| SCHEMBL462556 | 0.72 | SLC7A5 (0.46) | FOLH1METAP1 | |
| SCHEMBL417728 | 0.72 | SLC7A5 (0.46) | FOLH1METAP1 | |
| Butane SCHEMBL7716767 | 0.71 | FOLH1 (0.50) | FNTAFNTBFOLH1METAP1NAALAD2 | |
| SCHEMBL1572707 | 0.70 | CHRM1 (0.52) | METAP1 | |
| SCHEMBL4447254 | 0.70 | CHRM1 (0.52) | METAP1 | |
| SCHEMBL1304832 | 0.70 | FOLH1 (0.48) | FOLH1NAALAD2 | |
| SCHEMBL11329707 | 0.69 | FOLH1 (0.39) | FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |